Work

Abstract PD17-03: Cell-free DNA monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib for localized HR+/HER2- breast cancer (LEADER)

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs22-pd17-03

Authors: Arielle J. Medford, Lauren Scarpetti, Andrzej Niemierko, Steven J. Isakoff, Beverly Moy, Seth A. Wander, Elizabeth Deluca, Elizabeth Abraham, Jennifer Shin, Lowell Schnipper, Amy E. Comander, Therese Mulvey, Erik Spickard, Ekaterina Kalashnikova, Angel Rodriguez, Leif Ellisen, Aditya Bardia, Laura M. Spring

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Harvard University, Beth Israel Deaconess Medical Center, Newton Wellesley Hospital, Natera (United States)

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4322769171

Cites:

Cited by: 4

Related to: 10